Catalyst overview
Research summary
This catalyst tracks a Approved update for Oveporexton (Orexin Agonist) in Narcolepsy Type 1. The expected timing is based on the latest available company guidance and may change.
05/10/26:- Priority Review granted. Approval expected in FY2026-2027. U.S. launch planned in H2 2026. 06/15/26:- FirstLight and RadiantLight Phase 3 secondary endpoint results presented. PDUFA goal date is Q3 2026. 08/05/26:- FDA approved ORZEYFUL for adult NT1; DEA scheduling expected within 90 days.
Verification
Confirm timing and program details against the company announcement or filing.